2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. Doi: 10.1016/S0140-6736(05)66544-0.

3. Engel J., Eckel R., Kerr J., et al. The process of metastasisation for breast cancer. Eur J Cancer. 2003;39(12):1794–806. Doi: 10.1159/000323483.

4. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastas Rev. 1990;9(3):171–74. Doi: 10.1007/BF00046358.

5. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11–12):1727–33.

6. Fisher B., Gunduz N., Coyle J., et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Canc. Res. 1989;49(8):1996–2001. Heppner GH: In vitro studies on cell-mediated.

7. Heppner G.H. In vitro studies on cell-mediated immunity following surgery in mice sensitized to syngeneic mammary tumors. Int J Canc. 1972;9(1):119–25. Doi: 10.1002/ijc.2910090114.

8. Fisher B., Gunduz N., Saffer E.A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Canc Res. 1983;43(4):1488–92.

9. Kupstas A.R., Hoskin T.L., Day C.N., et al. Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: a national cancer database analysis. Ann Surg Oncol. 2019;26(10):3240–9. Doi: 10.1245/s10434-019-07566-7.

10. Downing A., Twelves C., Forman D., et al. Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast J. 2014;20(1):29–36. Doi: 10.1111/tbj.12209.

11. Chavez-MacGregor M., Clarke C.A., Lichtensz-tajn D.Y., et al. Delayed initiation of adjuvant chemotherapy among patients with breast Cancer. JAMA. Oncol. 2016;2(3):322–29. Doi: 10.1001/jamaoncol.2015.3856.

12. Nurgalieva Z.Z., Franzini L., Morgan R.O., et al. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013;30(1):419. Doi: 10.1007/s12032-012-0419-1.

13. Farolfi A., Scarpi E., Rocca A., et al. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer. 2015;51(14):1874–81. Doi: 10.1016/j.ejca.2015.07.003.

14. Shannon C., Ashley S., Smith I.E. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J ClinOncol. 2003;21(20):3792–97. Doi: 10.1200/JCO.2003.01.073.

15. Jara Sanchez C., Ruiz A., Martin M., et al. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM)

16. Cold S., During M., Ewertz M., et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)

17. Yu K.D., Huang S., Zhang J.X., et al. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC. Cancer. 2013;13:240. Doi: 10.1186/1471-2407-13-240.

18. Raphael M.J., Biagi J.J., Kong W., et al. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2016;160(1):17–28. Doi: 10.1007/s10549-016-3960-3.

19. Biagi J.J., Raphael M.J., King W.D., et al. The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): a systematic review and meta-analysis. JAMA. 2011;29(15):1128. Doi: 10.1200/jco.2011.29.15_suppl.1128.

20. Lohrisch C., Paltiel C., Gelmon K., et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-s tage breast cancer. J Clin Oncol. 2006;24(30):4888–94. Doi: 10.1200/JCO.2005.01.6089.

21. Gagliato D.M., Gonzalez-Angulo A.M., Lei X., et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014;32(8):735–44. Doi: 10.1200/JCO.2013.49.7693.

22. Morante Z., Ruiz R., Araujo J.M., et al. Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast Cancer. Clin Breast Cancer. 2021;21(3):239–46 e234. Doi: 10.1016/j.clbc.2020.09.008.

23. Ashok Kumar P., Paulraj S., Wang D., et al. Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. J Cancer Res Clin Oncol. 2021;147(8):2447–58. Doi: 10.1007/s00432-021-03525-6.

24. He X., Ye F., Zhao B., et al. Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: a systematic review and meta-analysis involving 186982 patients. PLoS One. 2017;12(3):e0173862. Doi: 10.1371/journal.pone.0173862.